News coverage about Viking Therapeutics (NASDAQ:VKTX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viking Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1172948602115 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Shares of Viking Therapeutics (VKTX) traded up $0.01 during mid-day trading on Monday, hitting $5.01. 806,000 shares of the company were exchanged, compared to its average volume of 1,122,300. The firm has a market capitalization of $146.40 and a P/E ratio of -5.89. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $5.19.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current year.

VKTX has been the subject of several research reports. Maxim Group restated a “buy” rating and issued a $5.00 price target on shares of Viking Therapeutics in a research note on Monday, September 11th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Viking Therapeutics in a research note on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a research note on Tuesday, November 21st. They issued a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Insider Buying and Selling by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with's FREE daily email newsletter.